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ABSTRACT
The alteration of miRNA processing is a driver event in several tumors including 
thyroid cancer. In particular, somatic DICER1 mutations, reported in follicular-
patterned lesions, are shared by benign as well as malignant tumors. In the present 
study, we investigated the effects of alterations in the miRNA processing genes on 
the miRNA profile.
The study included 19 follicular adenomas (FAs) and 22 follicular variant of 
papillary thyroid carcinomas (FVPTCs). The mutational status in the hot spot regions 
of DICER1, DROSHA, TARBP2, DGCR8 and the most commonly affected genes in 
thyroid tumors was investigated on both tumor and paired normal tissues. The miRNA 
profile and the mRNA expression levels of DICER1, DROSHA, TARBP2, DGCR8 and 
XPO5 were also evaluated.
Two DICER1 RNase IIIb domain mutations were found in FAs. These lesions 
presented a considerable loss of 5p miRNAs. Fifteen miRNAs were specifically 
deregulated in DICER1-mutant lesions compared to FAs and FVPTCs. These miRNAs 
regulate crucial pathways in cancer such as Hippo, p53 and TGF-beta signalling.
DICER1 somatic mutations in the RNase IIIb domain are not specific for 
malignancy, but the miRNA imbalance that they cause is remarkable, especially with 
regard to the loss of 5p miRNAs. DICER1-mutant lesions have a characteristic miRNA 
deregulation, which is different from that of FVPTCs; nevertheless, this impairment is 
consistent with malignant transformation. Further studies providing the real risk of 
malignancy associated with DICER1 mutations and the evolution of DICER1-mutant 
lesions are needed to make them useful in the clinical practice.
INTRODUCTION
The biogenesis of microRNAs (miRNAs) 
occurs in the nucleus and in the cytoplasm. In the 
nucleus, the microprocessor complex, composed by 
the ribonuclease DROSHA and by the RNA binding 
protein DGCR8 (DGCR8, microprocessor complex 
subunit), cleaves the primary transcripts of miRNAs 
(pri-miRNAs) in pre-miRNAs of about 70 nucleotides. 
Pre-miRNAs exit the nucleus by exportin 5 (XPO5), 
and in the cytoplasm they undergo further processing 
by the ribonuclease DICER1 and the RNA binding 
protein TARBP2 (TARBP2, RISC loading complex 
RNA binding subunit) [1]. This step produces mature 
miRNAs that will be assembled in the RNA-induced 
silencing complex in order to silence the expression 
of specific targets by translational repression, mRNA 
deadenylation and decay [2].
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The alteration of this machinery has been reported 
in several human cancers; however, the extent of this 
dysregulation is controversial. In fact, the effect of the 
up- or down-regulation of the miRNA processing genes 
seems to be tissue-specific [1, 3]. For instance, in some 
tumors like acute myeloid leukaemia, prostate and oral 
cancers, DICER1 is overexpressed both at the mRNA and 
the protein level. On the contrary, in other tumors such 
as lung, skin and breast cancers, low levels of DICER1 
mRNA or protein are associated with malignant lesions 
and poor prognosis [1].
Alongside expression alterations, mutations in 
the genes involved in the processing of miRNAs have 
been reported both at the somatic and germline levels 
[1, 3–5]. In particular, germline mutations in DICER1 
predispose individuals to multiple tumors, benign and 
malignant alike, including pleuropulmonary blastoma, 
cystic nefroma, embryonal rhabdomyosarcoma and 
multinodular goiter [1, 6]. As regards thyroid disorders, 
germline mutations in DICER1 are associated with a 
higher risk to develop not only benign conditions but 
also well-differentiated carcinomas [7]. Furthermore, 
somatic mutations, especially in the RNase IIIb domain, 
are potential driver events in well-differentiated thyroid 
cancer [8–10], probably leading to an imbalance in 
miRNA processing and in particular to a consistent loss of 
mature 5p miRNAs [11].
In this complex and variable scenario, we 
investigated the presence of mutations in the hot spot 
regions of genes involved in miRNA processing in 
follicular-patterned thyroid tumors. In detail, we focused 
on crucial regions considering both the functional domains 
and the presence of somatic mutations described in the 
literature. We also tested the presence of mutations in the 
most commonly affected genes in thyroid cancer. Finally, 
we evaluated the mRNA expression levels of DICER1, 
DROSHA, TARBP2, DGCR8 and XPO5, and the miRNA 
expression profile.
RESULTS
Clinico-pathological features
Among the 41 follicular patterned thyroid lesions, 
there were 19 follicular adenomas (FAs) and 22 follicular 
variant of papillary thyroid carcinomas (FVPTCs). None 
of the cases presented oncocytic aspects. Among the 22 
FVPTCs, nine were encapsulated non-invasive, eight 
encapsulated invasive, and five infiltrative. None of the 
encapsulated non-invasive lesions met the diagnostic 
criteria of non-invasive follicular thyroid neoplasms with 
papillary-like nuclear features [12, 13]. Overall, there were 
nine males and 32 females, the mean age was 44.4 ± 15.5 
years and the mean size was 36 ± 16 mm. There were no 
differences between FAs and FVPTCs in terms of gender, 
age and size.
Mutational status and mutation prediction
Overall, 14 somatic and four germline mutations 
were found in heterozygosis. Briefly, eight out of 14 
somatic mutations were NRAS, four HRAS and two 
DICER1. No PAX8-PPARG rearrangements were detected, 
and no mutations were found in BRAF, KRAS, DGCR8 
and TARBP2. Both DICER1 mutations were detected in 
FAs. All germline mutations were synonymous DROSHA 
variants, two were p.S981S and two were p.Y1199Y. Two 
DROSHA germline mutant carriers also harbored RAS 
mutations. Three out of 14 somatic mutations were found 
in FAs, whereas 11 were detected in FVPTCs. Germline 
mutations were equally split between FAs and FVPTCs. 
Details are shown in Table 1. Germline DROSHA 
mutations were already reported as single nucleotide 
variants, rs17485810 (p.S981S) and rs61748189 
(p.Y1199Y). However, the minor allele frequencies on 
Exome Aggregation Consortium (ExAC) [14] and 1000 
Genomes [15] were 0.0032 and 0.0028 for rs17485810, 
and 0.0080 and 0.0038 for rs61748189, respectively. Both 
variants were predicted to be disease causing by Mutation 
Taster (without amino acid exchange model, prob=1); in 
detail, p.S981S affects a splicing site, whereas p.Y1199Y 
involves a CG-rich region, potentially affecting Histone 
3 Lysine 36 Tri-Methylation. Patients carrying DROSHA 
germline mutations were younger than the others, but the 
p value was not significant (p=0.0633).
miRNA expression analyses
A total of 143 miRNAs were considered after 
normalization. The principal component analysis (PCA) 
produced 41 principal components; the first two accounted 
for 41.7% of variance and were used for plotting. As 
illustrated in Figure 1, FA8 and FA19, both harboring 
DICER1 mutations, mostly contributed to the variance. 
Hierarchical clustering showed that the miRNA profiles 
of the two DICER1 mutated cases were highly correlated 
(Figure 2). 5p and 3p percentages were defined as the 
proportion of cumulative 5p and 3p miRNA normalized 
counts on the total of normalized miRNA counts per 
sample, respectively. All samples had a predominance 
of 5p miRNAs, except for the two DICER1-mutant FAs 
(Figure 3).
Twenty-two, 29 and 28 miRNAs were differentially 
expressed by contrasting FAs versus DICER1-mutant FAs, 
FVPTCs versus DICER1-mutant FAs and FAs versus 
FVTPCs, respectively. Some of these miRNAs were 
differently expressed in more than one comparison, but 
17 were specifically deregulated in FVPTCs compared to 
FAs. Finally, 15 miRNAs were deregulated in DICER1-
mutant FAs versus both DICER1-negative FVPTCs 
and FAs (Figure 4 and Table 2). These 15 miRNAs 
were then tested for pathway enrichment analysis to 
highlight pathways deregulated in DICER1-mutant 
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lesions. Twenty-four pathways were enriched, and fatty 
acids synthesis and metabolism were among those with 
the highest confidence. In addition, crucial pathways in 
cancer such as Hippo, p53 and TGF-beta signalling were 
also enriched (Figure 5).
mRNA expression levels
The expression levels of DGCR8, DICER1, 
DROSHA, TARBP2 and XPO5 were not significantly 
different between FAs and FVPTCs. However, the 
two DICER1 mutated FAs had high mRNA levels of 
DICER1 (Figure 6A). Likewise, the two lesions harboring 
DROSHA p.Y1199Y variant had high levels of DROSHA 
mRNA (Figure 6B).
TCGA data analysis
Three TCGA cases harbored DICER1 mutations 
(0.6%); two of these cases were in the RNase IIIb 
domain (one p.E1813G and one p.D1810H) and one in 
the double strand RNA-binding domain (p.R1906S). The 
mutations in the RNase IIIb domain did not coexist with 
RAS or BRAF mutations, whereas the case harboring 
DICER1 p.R1906S had a concomitant NRAS p.Q61R. 
Further details are reported in Table 3. Two cases (0.5%) 
harbored mutations in the double strand RNA-binding 
domain of DGCR8 (two p.E518K), but they both had 
a concomitant NRAS mutation. One of the two cases 
harboring DGCR8 p.E518Kshowed no consistent loss of 
5p miRNAs.
Figure 1: Principal component analysis. All the 143 miRNAs considered were used in the analysis. Principal components 1 and 2 
accounted for 41.7% of variability and were used for plotting. DICER1 mutated cases (FA8 and FA19) mostly contributed to the variance 
as highlighted by squared cosine (cos2).
Table 1: Mutational status
Histology NRAS HRAS DICER1 DROSHA
FAs (n=19) 1 p.Q61R(c.182 A>G) -
1 p.D1810V
(c.5429 A>T)
1 p.E1813K
(c.5437 G>A)
1 p.S981S
(c.2943 C>T)
1 p.Y1199Y
(c.3597 C>T)
FVPTCs (n=22) 7 p.Q61R(c.182 A>G)
4 p.Q61R
(c.182 A>G)
1 p.S981S
(c.2943 C>T)
1 p.Y1199Y
(c.3597 C>T)
FAs follicular adenomas; FVPTCs follicular variant of papillary thyroid carcinomas.
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DISCUSSION
In the deep sequencing era, there is an urgent need 
for the discovered mutations to be contextualized so 
that they may be helpful in the clinical practice. Thyroid 
cancer is a paradigm for the use of molecular information 
in the clinical field, especially for diagnostic purposes. 
Follicular-patterned lesions are the major challenge in the 
pre-surgical diagnosis of thyroid nodules; for this reason, 
they are frequently sequenced in order to find mutations 
that could help to distinguish benign from malignant 
lesions [8–10]. This deep sequencing unearthed several 
somatic mutations previously unknown. Among these, 
DICER1 mutations were formerly known as germline 
mutations, which are associated with the so-called 
DICER1-syndrome and predispose carriers not only to 
multinodular goiter but also to pleuropulmonary blastoma, 
cystic nefroma and embryonal rhabdomyosarcoma. 
Although somatic DICER1 mutations have not been 
extensively studied in thyroid cancer, it is accepted that 
they are driver events [6, 7]. However, their potential 
usefulness in the clinical practice is still questionable, 
also because they are shared by both benign and malignant 
lesions [9]. In this scenario, we sought to contextualize 
genetic alterations in DICER1 and in the other miRNA 
processing genes concerning the molecular dysregulations 
Figure 2: Hierarchical clustering. All the 143 miRNAs (rows) and samples (columns) were independently clustered using Pearson’s 
correlation. Sidebars show the histological class and the mutational status. Black arrows emphasize the two DICER1 mutant FAs. FA 
follicular adenoma, FVPTC follicular variant of papillary thyroid carcinoma.
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they produce, in order to provide important information 
for clinical decisions in presence of lesions harboring 
these alterations.
Our series confirmed that somatic DICER1 
mutations have never coexisted with the most common 
driver mutations in thyroid cancer. However, the two 
DICER1 mutated cases were FAs: despite the benign 
nature of these lesions, PCA highlighted the entity of 
miRNA dysregulation (Figure 1), and the miRNA profile 
of the two lesions harboring DICER1 p.D1810V and 
p.E1813K was very similar (Figure 2). The dysregulation 
mainly affected 5p miRNAs (Figure 3), as previously 
reported in other cancer models [11]. In spite of the low 
number of DICER1-mutants and the consequent low 
statistical power, several miRNAs were deregulated when 
contrasting FAs harboring DICER1 mutations with both 
FVPTCs and FAs (Table 2). Consistently with the previous 
analysis, all differently expressed 5p miRNAs were 
downregulated in DICER1-mutant group with respect 
to FAs as well as FVPTCs. Interestingly, there was very 
little overlap between miRNAs deregulated in FVPTCs 
and in DICER1-mutants versus FAs (Figure 4). Moreover, 
15 miRNAs were specifically deregulated in DICER1-
mutants. These miRNAs were then tested for pathway 
Figure 3: 3p and 5p percentages. Percentages were defined as the amount of 3p and 5p miRNAs out of the total. DICER1 mutated 
cases, highlighted by black arrows, had a remarkable reduction of 5p miRNAs.
Figure 4: Venn diagram of differentially expressed miRNAs. 
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enrichment analysis to identify pathways affected by such 
a deregulation. The analysis showed that these miRNAs 
are crucial in several pathways (Figure 5), and not only 
metabolic ones or pathway fitting benign conditions such 
as fatty acids metabolism, but they also regulate pathways 
with a pivotal role in cancer, such as Hippo, p53 and 
TGF-beta [16, 17]. In addition, adherens junction and 
proteoglycan pathways also seem to be affected, and they 
are known to be involved in the malignant transformation 
due to the gaining of an invasive potential [18, 19].
As concerns DROSHA germline mutations, 
p.S981S and p.Y1199Y have been previously described 
in both ExAC and 1000 Genomes, in which individuals 
with evident diseases have been removed. However, the 
frequencies of these variants were considerably lower 
than the 0.01 cut-off value for polymorphisms, but were 
much higher in our series. This difference could be due to 
chance, but there was also an interesting trend for these 
DROSHA germline mutant carriers to be younger than the 
other patients were.
Indeed, our study suffers from some limitations such 
as low number of samples, especially DICER1 mutants. 
Although we did not perform a functional analysis of 
DICER1 mutations, our results are consistent with the 
findings of Anglesio et al. regarding engineered mice 
embryonal stem cells, in which mutations affecting 
the heme-binding residues in the RNase IIIb domain of 
DICER1 resulted in a loss of mature 5p miRNAs [11]. 
Moreover, we confirmed our findings with TCGA data, in 
which cases harboring DICER1 mutations in the RNase 
IIIb domain never coexisted with other well-known driver 
mutations in thyroid cancer. Although these cases had 
a high expression level of DICER1 mRNA, they had a 
remarkable reduction in mature 5p miRNAs (Table 3).
To sum up, our study provided further evidences 
of the involvement of the miRNA processing genes and 
Figure 5: Pathway enrichment analysis. The 15 DICER1-specific miRNAs were used in the analysis to predict the pathways that 
could be affected.
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Table 2: miRNA differential expression analysis
FAs vs DICER1-mutant FAs FVPTCs vs DICER1-mutant FAs FAs vs FVPTCs
miRNA log FC FDR log FC FDR log FC FDR
hsa-miR-106a-5p + 
hsa-miR-17-5p -3.32 0.0009
hsa-miR-106b-5p -4.47 0.0079 -2.07 0.0281
hsa-miR-126-3p 2.57 0.0100 -0.81 0.0343
hsa-miR-135a-5p -2.65 0.0076
hsa-miR-135b-5p -5.61 0.0002 -4.86 0.0007
hsa-miR-146b-5p 3.29 0.0322
hsa-miR-148b-3p 2.92 0.0144 3.65 0.0029
hsa-miR-151a-5p -4.89 0.0041
hsa-miR-152-3p 7.62 <0.0001 -2.61 0.0130
hsa-miR-15b-5p -3.45 0.0076 -2.70 0.0273
hsa-miR-181a-3p 5.57 0.0012 5.36 0.0010
hsa-miR-181a-5p -1.96 0.0487
hsa-miR-185-5p -2.10 0.0199
hsa-miR-191-5p -2.92 0.0009 -2.56 0.0025
hsa-miR-195-5p -2.70 0.0281
hsa-miR-19a-3p 6.80 0.0034 -2.12 0.0482
hsa-miR-19b-3p 3.75 0.0100 -1.06 0.0495
hsa-miR-200c-3p 2.69 0.0218
hsa-miR-204-5p -2.87 0.0465
hsa-miR-221-3p 3.80 0.0343
hsa-miR-222-3p 2.46 0.0192
hsa-miR-20a-5p + hsa-
miR-20b-5p -3.08 0.0222 -3.29 0.0030
hsa-miR-25-3p 2.12 0.0487
hsa-miR-28-5p -2.61 0.0123 -1.72 0.0394
hsa-miR-296-5p -2.40 0.0130
hsa-miR-301a-3p 4.18 0.0136 5.55 0.0273
hsa-miR-30c-5p -6.18 0.0003 -5.22 0.0004
hsa-miR-30d-5p -2.92 0.0123 -2.78 0.0025
hsa-miR-30e-3p 5.61 0.0281 -2.97 0.0130
hsa-miR-30e-5p -3.90 0.0037 -3.00 0.0042 -0.90 0.0495
hsa-miR-3151-5p -3.63 0.0025
hsa-miR-32-5p -6.61 0.0002 -5.93 0.0011
hsa-miR-331-3p -2.30 0.0322
hsa-miR-340-5p -2.25 0.0458
hsa-miR-34a-5p -4.40 0.0006 -4.55 <0.0001
hsa-miR-361-3p -2.59 0.0192
hsa-miR-361-5p -5.47 0.0076 -5.38 0.0001
(Continued)
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FAs vs DICER1-mutant FAs FVPTCs vs DICER1-mutant FAs FAs vs FVPTCs
hsa-miR-363-3p -2.20 0.0488
hsa-miR-365a-3p + 
hsa-miR-365b-3p -2.51 0.0343
hsa-miR-374b-5p -4.54 0.0158 -1.80 0.0495
hsa-miR-423-3p -5.21 0.0002 -2.55 0.0130
hsa-miR-424-5p -4.66 0.0025
hsa-miR-4286 4.02 0.0173 3.89 0.0218
hsa-miR-429 8.65 0.0006 8.46 0.0010
log FC FDR log FC FDR log FC FDR
hsa-miR-4454 + hsa-
miR-7975 1.28 0.0343
hsa-miR-4516 2.33 0.0480
hsa-miR-451a 2.37 0.0218
hsa-miR-454-3p 5.50 0.0174 -2.36 0.0281
hsa-miR-518b -3.24 0.0130
hsa-miR-5196-3p + 
hsa-miR-6732-3p -2.83 0.0192
hsa-miR-660-5p -2.30 0.0385
hsa-miR-98-5p -2.20 0.0135 -1.88 0.0218
Abbreviations: FAs, follicular adenomas; FVPTCs, follicular variant of papillary thyroid carcinomas; FC, fold change; 
FDR, false discovery rate.
Figure 6: DICER1 and DROSHA expression levels. Histograms represent the log-fold change expression of DICER1 (A) and 
DROSHA (B) mRNA calculated by the ΔΔCt method. The two DICER1 mutants (A) and DROSHA p.Y1199Y (B) carriers are emphasized 
by black arrows. Grey arrows highlight DROSHA p.S981S carriers.
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Table 3: TCGA data analysis of DICER1 mutant cases
ID TCGA-EL-A3D5 TCGA-EL-A3GO TCGA-EM-A2CT
Histology CVPTC CVPTC FVPTC
DICER1 mutation E1813G D1810H R1906S
DICER1 mutation domain RNase IIIb RNase IIIb double-stranded RNA binding
Other mutations
TP53
NCAN
NAB2
ABCB11
RPAP1
TSPYL2
AMDHD1
E343Afs*3
P1274S
L495Cfs*22
Q216*
L628R
X413_splice
D334Ifs*20
SHQ1
ARHGEF6
SLITRK3
TECPR1
DNAH1
HEATR6
DYNC2H1
SBF2
CSMD2
CCDC24
OR51F1
STAC2
D13H
W439C
R809W
W763Gfs*56
R4133S
K437N
G1396Efs*2
I1545S
M2857T
A44V
K306N
E241K
NRAS
IRS1
TP73
SYNJ2
OSMR
WDR7
NGEF
KRTAP4-12
SLC9A4
Q61R
M664I
E40G
S1032Y
D692G
X1277_
splice
L681P
R192H
K622N
Copy number alteration PDE3A AMP PTPRT AMP
DUSP22
IRF4
EXOC2
HUS1B
SLC8A1
CBLN2
NETO1
LINC01541
LOC400655
LINC02582
AMP
AMP
AMP
AMP
DEL
AMP
AMP
AMP
AMP
AMP
Putative driver DICER1 E1813G DICER1 D1810H NRAS Q61R
DICER1 mRNA 
expression percentile 99.18 99.59 60.29
5p miRNA percentage 
percentile 0.18 0.53 7.03
Abbreviations: CVPTC, classic variant of papillary thyroid carcinoma; FVPTC, follicular variant of papillary thyroid 
carcinoma; AMP, amplification; DEL, deletion.
Figure 7: Current knowledge of DICER1 IIIb somatic mutations in thyroid tumors based on the present study results and 
on the literature data. Owing to the lack of data, the impact of these mutations on prognosis is unknown. *based on the clinical context.
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of miRNA dysregulation in thyroid cancer. There are 
some points that need to be highlighted: a) DROSHA 
rs17485810 and rs61748189 germline variants could be 
predisposing, but not sufficient factors for thyroid tumors, 
as demonstrated by the co-occurrence of RAS mutations; 
b) DICER1 somatic mutations are not specific markers 
for malignancy, and further studies providing sufficient 
follow-up data, real frequencies and, most importantly, 
the risk of malignancy associated with them are needed; 
c) DICER1 somatic mutations in the RNase IIIb domain 
strongly impair miRNA processing; d) the deregulation of 
miRNAs in DICER1-mutants is peculiar and different from 
that in FVPTCs. When detected preoperatively, DICER1 
mutations could then suggest a surgical approach to these 
lesions, since tumors harboring DICER1 mutations are 
very different from wild-type ones, regardless of their 
benign or malignant nature, and similarly to RAS mutants 
they conceal deep molecular alterations with the potential 
of evolving in malignant forms (Figure 7).
In conclusion, although sufficient follow-up data 
of DICER1-mutant lesions is necessary to provide a 
definitive answer to this issue, the remarkable molecular 
alterations caused by these mutations should be taken into 
account in clinical decision-making.
MATERIALS AND METHODS
Study population
The study included 41 samples retrospectively 
collected from the archives of the section of Pathology 
of the University Hospital of Pisa. Only the most com-
mon follicular-patterned lesions were selected—i.e., FA 
and FVPTC. Hematoxylin and eosin stained sections 
were independently reviewed by two pathologists (F.B. 
and L.T.). The lesions were diagnosed according to the 
World Health Organization 2017 diagnostic criteria [20]. 
FAs were submitted in toto to exclude the presence of 
vascular or capsular invasion. The study conformed to 
the principles of the Helsinki Declaration of 1975, it was 
conducted anonymously, and no sensitive data was used.
Nucleic acids purification and mutational 
analyses
For each sample, four unstained 10μm- and 5μm-thick 
formalin-fixed and paraffin-embedded (FFPE) sections 
were used for DNA and RNA purification, respectively. 
Unstained sections were deparaffinized in xylene and 
Table 4: Primers used for sequencing selected exons of the miRNA processing genes
Gene Transcript ID Exon Functional domain Primers
DICER1 ENST00000343455.7
24
RNase IIIb
F: AAGCTTACGGTTCCACTTCG
R: ACCACTATGCCGTCAGAACT
25
F1: AGAATAATAAATGGGGTGGGGAT
R1: GTACACCTGCCAGACTGTCT
F2: AACTACATCTGTGGACTGCC
R2: TCAAGCAATTCTCGCACAGG
DROSHA ENST00000511367.6
23
RNase IIIa
F: TGTGTTCTTTTCTTGCGGGG
R: ACACGGTGTATCAATGCCTT
24
F: TCAGAGCCACAGACAGAATGT
R: ACCGCAGAAGAGCATGTCA
29
RNase IIIb
F: TCAATCGAGGGGCCTTAGG
R: TGGAGGAAGTGATTTAACCAACT
30
F: TGTTCTCAATGTACCGCCAT
R: AGGAGGAGGACAAATACGGT
DGCR8 ENST00000351989.7 7 heme- and pri-miRNA binding
F: GTGGCACTGCTTCACACTTG
R: GCCCTGACCAAAGTTACACC
TARBP2 ENST00000266987.6
7
DICER1- and pre-miRNA 
binding
F: GGTCTGTGGGGAATCATAACC
R: CAGAAGCAGACCTAGGGCC
8
F: TCGCTTCATCTTTCTCACTGT
R: CCCTTCTACTTGCTCCGGTC
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then rehydrated in ethanol solutions. After manual macro-
dissection, DNA and total RNA were isolated by the 
QIAamp DNA Mini Kit (Qiagen Inc, Hilden, Germany) and 
the miRNeasy FFPE Kit (Qiagen Inc, Hilden, Germany) 
respectively, according to the manufacturer’s protocols. 
Quantity and quality of nucleic acids were assessed by 
spectrophotometry (Xpose Trinean, Gentbrugge, Belgium).
The mutational status of BRAF (exon 15), the RAS 
genes (exons 2–3), DICER1 (exons 24–25), DROSHA 
(exons 23–24,29–30), DGCR8 (exon 7) and TARBP2 
(exons 7–8) were analysed by direct sequencing (3130 
Genetic Analyzer, Applied Biosystems, Foster City, 
CA, USA), according to standard procedures [21]. Primers 
used for sequencing miRNA processing genes are reported 
in Table 4. In addition, the presence of PAX8-PPARG 
rearrangements (exons 7 and 9) was investigated, as 
previously described [22]. The paired normal tissues from 
the contralateral lobe or the normal collateral parenchyma 
of lesions harboring mutations in the miRNA processing 
genes were used to confirm the germline or somatic nature 
of the variants according to current guidelines [23]. To 
ensure that the tissue was normal, without tumor foci, 
sections above and below those used for nucleic acids 
isolation were stained with hematoxylin and eosin and 
independently reviewed by two pathologists.
Expression analyses
The expression profiling of 798 miRNAs was 
carried out by the nCounter human v3 miRNA expression 
assay (NanoString Technologies, Seattle, WA, USA), as 
previously described [24].
The expression levels of DICER1, DROSHA, 
TARBP2, DGCR8 and XPO5 were evaluated by RT-PCR 
using the QuantiTect Primer Assay (Qiagen Inc, Hilden, 
Germany), and following the manufacturer’s instructions. 
In detail, the retrotranscription step was performed using 
the RevertAid First Strand cDNA Synthesis Kit (Thermo 
Scientific, Waltham, MA), as previously reported [22]. 
Fifty ng of cDNA were then used in a reaction volume of 
25 μL with the Rotor-Gene SYBR Green PCR Master Mix 
(Qiagen Inc, Hilden, Germany), and with specific primers. 
Amplification was performed in 40 cycles (denaturation at 
95°C for 5 sec, annealing and elongation at 60°C for 10 
sec). Actin beta (ACTB) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were used as housekeeping 
genes, and thyroglobulin (TG) was used as specificity 
control. Each sample was amplified in double copy. The 
ΔΔCt method was used to assess the relative quantification 
of the targets [25].
Statistical analyses
miRNA expression counts were normalized 
according to the manufacturer’s instructions. In detail, 
background thresholding was applied to raw counts 
by using the max value of the negative control counts 
as threshold. In addition, only miRNAs with counts 
above the threshold in more than 60% of samples 
were considered for further analyses. PCA was used 
to summarize the variation pattern of the dataset. 
Hierarchical clustering was performed using Pearson’s 
correlation and average as distance and clustering 
functions, respectively. The moderated t-statistics was 
used to evaluate the miRNA differential expression. After 
normal distribution assessment by the Shapiro-Wilk’s 
test, continuous variables were tested by the two-tailed 
Student’s t test. Fisher’s exact test was used to analyse 
categorical variables. miRNA pathway analysis was 
performed by the mirPath v.3 web server [26]; for the 
analysis, KEGG and TarBase v.7.0 were used as pathway 
and miRNA reference databases, respectively. In addition, 
the analysis was performed using the a posteriori method 
“pathway union” by a modified Fisher’s exact test. All 
p values were adjusted with the Benjamini-Hochberg’s 
correction, and FDR of 0.05 was set as significance level. 
The prediction of the effect of uncommon mutations 
was conducted by Mutation Taster [27]. The mutational 
status of DGCR8, DICER1, DROSHA and TARBP2 
of thyroid cancer TCGA cases was explored by using 
the cBioportal (http://www.cbioportal.org); level 3 
miRNA expression data was downloaded from FireHose 
(http://gdac.broadinstitute.org). All statistical analyses were 
performed in R environment (http://www.R-project.org).
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